Jennifer L Taylor-Cousar Selected Research

ivacaftor drug combination tezacaftor

1/2022	Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.
1/2022	Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy.
1/2021	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
1/2021	Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
1/2021	Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
1/2021	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
11/2019	Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
1/2019	The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
10/2018	VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
10/2018	VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jennifer L Taylor-Cousar Research Topics

Disease

40	Cystic Fibrosis (Mucoviscidosis) 11/2022 - 09/2007
6	Lung Diseases (Lung Disease) 11/2021 - 01/2009
5	Infections 01/2022 - 01/2009
4	Inflammation (Inflammations) 01/2022 - 01/2010
3	Rhinosinusitis 11/2022 - 01/2022
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 01/2018
2	Urinary Incontinence 01/2022 - 01/2021
2	Osteoporosis 01/2021 - 01/2020
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2022
1	Hemoptysis 01/2022
1	Bronchiectasis 12/2021
1	Headache (Headaches) 11/2021
1	COVID-19 01/2021
1	Infertility (Sterility) 01/2021
1	Pseudomonas Infections 01/2020
1	Joint Diseases (Joint Disease) 01/2019
1	Exocrine Pancreatic Insufficiency 01/2019
1	Respiratory Insufficiency (Respiratory Failure) 01/2018
1	Cough 03/2016
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2016
1	Virus Diseases (Viral Diseases) 01/2016
1	Sclerosis 11/2014
1	Hypoventilation 06/2009
1	Fibrosis (Cirrhosis) 11/2007

Drug/Important Bio-Agent (IBA)

12	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2022 - 11/2014
11	ivacaftor drug combination tezacaftorIBA 01/2022 - 11/2017
9	elexacaftorIBA 01/2022 - 10/2018
6	ChloridesIBA 01/2021 - 11/2014
6	ivacaftorIBA 11/2019 - 12/2015
4	Azithromycin (Zithromax)FDA LinkGeneric 01/2021 - 03/2014
4	lumacaftorIBA 01/2018 - 12/2015
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 03/2016
3	Pharmaceutical PreparationsIBA 11/2021 - 05/2017
3	Tobramycin (Nebcin)FDA LinkGeneric 01/2019 - 03/2014
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2019
2	tezacaftorIBA 11/2019 - 11/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	leukotriene A4 hydrolaseIBA 11/2021
1	acebilustatIBA 11/2021
1	riociguatIBA 11/2021
1	Estrogens (Estrogen)FDA Link 01/2020
1	Progestins (Progestagens)IBA 01/2020
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 01/2020
1	Contraceptive Agents (Contraceptives)IBA 01/2020
1	AnionsIBA 04/2019
1	colistinmethanesulfonic acid (colistimethate sodium)FDA LinkGeneric 01/2019
1	Methicillin (Metin)FDA Link 01/2019
1	VX-659IBA 10/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	C-Reactive ProteinIBA 01/2018
1	cavosonstatIBA 05/2017
1	InterferonsIBA 01/2016
1	Interferon Type IIBA 01/2016
1	SaltsIBA 12/2015
1	N 30IBA 11/2014
1	Oxygen (Dioxygen)IBA 06/2009
1	Blood Group Antigens (Blood Groups)IBA 01/2009
1	Bacterial ToxinsIBA 11/2007
1	FurinIBA 11/2007
1	ExotoxinsIBA 11/2007
1	Phosphodiesterase 5 InhibitorsIBA 09/2007

Therapy/Procedure

16	Therapeutics 11/2022 - 06/2009
2	Contraception (Birth Control) 01/2022 - 01/2021
1	Lung Transplantation 03/2020
1	Aftercare (After-Treatment) 01/2018
1	Contraceptive Effectiveness 11/2017
1	Immunomodulation 01/2016
1	Noninvasive Ventilation 06/2009